• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
3-Bromo-4-fluorobenzaldehyde
5-Methyl-1,3,4-oxadiazol2(3H)-one
4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride
4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine
3-Pyridinecarboxaldehyde
Ethyl 3 Fluorobenzoate

MSN group gets US FDA nod for dimethyl fumarate capsules

expresspharmaOctober 10, 2020

Tag: MSN , FDA , dimethyl fumarate capsules , ANDA

MSN Group (MSN), receives ANDA approval for dimethyl fumarate delayed release capsule. The company manufactures active pharmaceutical ingredient (API) as well as the finished formulation of dimethyl fumarate delayed-release capsules in-house.

MSN has entered into a commercial partnership with Dr Reddy’s for marketing the product in the United States.

The medicine will be available in strengths of 120 mg and 240 mg capsules in bottle count sizes of 14 and 60 capsules, respectively.

Dimethyl fumarate is a prescription medicine used to treat relapsing forms of multiple sclerosis in adults.
Currently, the company has over 100 ANDAs and 710 DMFs.

Previous:FDA issues guidance on emergency use authorisation for COVID-19 vaccines

Next:China’s experimental COVID-19 vaccine appears safe: study

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

MSN group gets US FDA nod for dimethyl fumarate capsules | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

HFHA(m-6FDAP)

HFHA(m-6FDAP)
Tacrolimus (FDA)

Tacrolimus (FDA)
Ferric Pyrophosphate Food Grade Manufacture USP Bp FCC Standard

Ferric Pyrophosphate Food Grade Manufacture USP Bp FCC Standard
Flame Retardant Grade Expandable Polystyrene

Flame Retardant Grade Expandable Polystyrene
LGJ-18S Multi Manifold Standard Type Experimental Freeze Dryer

LGJ-18S Multi Manifold Standard Type Experimental Freeze Dryer
Hydroxypropyl Betadex Oral Pharma Grade USP EP Standard

Hydroxypropyl Betadex Oral Pharma Grade USP EP Standard
Aciclovir (FDA)

Aciclovir (FDA)
Praziquantel (FDA)

Praziquantel (FDA)
Marya GMP Standard Electronic Pharmaceutical Cleanroom Cargo Air Shower with High Efficiency System

Marya GMP Standard Electronic Pharmaceutical Cleanroom Cargo Air Shower with High Efficiency System
Fully automatic standard PFS injection pen

Fully automatic standard PFS injection pen

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service